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Abstract 
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering 
skin disease and is characterized by the presence of autoantibodies directed against 
the hemidesmosomal proteins BP180 and BP230 that can be detected in the skin 
and serum of BP patients. Histologically, the dermal infiltration of eosinophils is 
obvious. The objective of this review is to present evidence that eosinophils play a 
key role in the pathogenesis of BP. Eosinophils, together with cytokines and 
chemokines regulating their production, recruitment and activation, are abundantly 
present in lesional skin, in blisters and in peripheral blood of patients with BP. 
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Recently, using a cryosection model, eosinophils were demonstrated to induce 
dermal-epidermal separation in the presence of BP antibodies. Thus, eosinophils 
and their products, as well as mediators regulating their function, present promising 
targets for the treatment of BP. 
 
Introduction 
Bullous pemphigoid (BP) is the most common autoimmune, subepidermal blistering 
disease of the skin, mainly affecting elderly people. With the present aging 
demography, the incidence of BP has been increasing (1). In general, BP presents 
with a symmetrical, often generalized, severely itchy eruption of vesicles and blisters 
on eczematous and/or urticarial infiltrated lesions associated with severe pruritus (2). 
The diagnosis should be confirmed by histopathology, direct immunofluorescence 
analyses and immune serological tests (3). Characteristic for BP is the presence of 
autoantibodies directed against the hemidesmosomal proteins BP180 (BPAG2, 
collagen XVII) and BP230 (BPAG1epidermal isoform) that can be detected in the 
peripheral blood as well as skin of BP patients (3). Specifically, BP180 
autoantibodies have been shown to play a crucial pathogenic role as they trigger an 
inflammatory cascade with subsequent tissue damage, and ultimately, blister 
formation (4, 5). 
 
The management of BP should be stepwise and comprises topical and 
systemic corticosteroids, tetracycline with nicotinamide, dapsone, 
immunosuppressive drugs, e.g. azathioprine, methotrexate, mycofenolate and 
chlorambucil, as well as rituximab, omalizumab, intravenous immunoglobulins, and 
immunoadsorption for severe, refractory cases (3). These therapies have been 
proven to be effective in randomized trials or case series, however, they are often 
associated with serious adverse effects, in particular in elderly patients. Therefore, a 
better understanding of the cellular and molecular mechanisms of BP, as well as the 
development of targeted therapies, should be addressed for the unmet needs of BP 
patients. Most insights in the pathogenesis of BP have come from animal models, 
but until the present, little has been reported about the potential role of eosinophils 
that are prominent skin infiltrating cells in human BP.  
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Eosinophils: multifaceted immune cells 
Despite the fact that the skin is normally devoid of eosinophils, eosinophil infiltration 
can be found in a broad spectrum of infectious, allergic, autoimmune, and neoplastic 
skin diseases (6). So far, information about a direct pathogenic role of eosinophils in 
skin diseases is scarce; indeed most knowledge about eosinophil function has been 
generated in the context of parasitic infections, bronchial asthma and 
hypereosinophilic syndromes. Blood eosinophilia derives from either mutations or 
gene fusions in the genome of the eosinophils (intrinsic eosinophilia) or increased 
production and release of cytokines affecting eosinophils by inflammatory or tumor 
cells (extrinsic eosinophilia) (7). Eosinophils are generated in and differentiate in the 
bone marrow from where they are released into the circulation. In the peripheral 
blood, they represent 1% to 5% of the leukocytes under physiologic conditions (8). 
Interleukin (IL)-3, IL-5, and GM-CSF represent eosinophil hematopoietins regulating 
the production, differentiation, activation, trafficking, and survival of eosinophils (9, 
10).  
 
Eosinophils are innate immune cells. Their primary function has been related 
to host defense, in particular, the protection against helminth parasites (11). By 
generating extracellular DNA nets associated with toxic granule proteins, the so 
called eosinophil extracellular traps (EETs), eosinophils have been shown to bind 
and kill bacteria (12, 13). On the other hand, the toxic granule proteins normally 
released to defend against infections, also cause tissue damage (11, 14). Although 
eosinophils expressing MHC class II can serve as antigen presenting cells, they are 
relatively inefficient when compared to dendritic cells or other professional antigen-
presenting cells (15). In addition, eosinophils play an important role in repair and 
remodeling processes as well as in immunomodulation (16, 17). For instance, 
eosinophils contribute to tissue fibrosis and remodeling since they express mediators 
such as fibroblast growth factor (FGF)-2, IL-4, IL-6, IL-11, IL-13, IL-17, IL-25, TGF-β, 
nerve growth factor (NGF), matrix metalloproteinase (MMP)-9 and vascular 
endothelial growth factor (VEGF) (18, 19). By producing the proliferation-inducing 
ligand April, eosinophils support the survival of plasma cells that are the main 
producers of antibodies (20). Depending on the inflammatory milieu, eosinophils can 
modulate either T helper (Th) 1 or Th2 immune responses by releasing cytokines 
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such as IL-2, IL-12, IL-18, and IFN-γ or IL-4, IL-5, IL-13, and IL-25 (16, 21-25). The 
characterization of the cytokine expression by eosinophils in lesional skin revealed 
typical patterns distinctive for infectious, allergic, autoimmune and tumor diseases 
(6). To note, eosinophils that respond to IL-31-mediated chemotaxis and activation 
may themselves release IL-31 and thus might be contributing to the pruritus 
associated with BP (26) (Figure 1). 
 
Eosinophils are potent effector cells, equipped with weapons that are stored in 
cytoplasmic granules: primary and secondary granules, small granules and lipid 
bodies (27). The cytotoxic cationic proteins that are stored in the secondary granules 
are formed by a core containing major basic protein (MBP) and a matrix composed 
of eosinophil cationic protein (ECP), eosinophil peroxidase (EPO) and eosinophil 
derived neurotoxin (EDN) (28). MBP is highly cytotoxic as it affects the charge of 
surface membranes resulting in disturbed permeability, disruption and injury to cell 
membranes (29, 30). Moreover, the toxicity of MBP has been shown to be regulated 
by aggregation (31). ECP forms pores or transmembrane channels in target cell 
membranes (32). ECP and EDN have been identified as ribonucleases (33) and 
possess antiviral activity (34). Eosinophils store abundant amounts of ECP and may 
release it upon repeated stimulation with the same agonist, implying that mature 
eosinophils do not require a significant ECP re-synthesis (35). Moreover, they are a 
source of MMP-9 that is released upon stimulation with IL-5, enabling eosinophil 
migration through basement membranes (36).  
 
Eosinophil inflammation in BP 
Eosinophil infiltration is a prominent feature of BP (Figure 1). Eosinophils are located 
in the upper dermis, often lining the dermal-epidermal junction. They can also be 
found in blisters. In hematoxylin & eosin (H&E) stained skin specimens, eosinophils 
can easily be identified as round cells stuffed with coarse eosinophil granules. 
Immunofluorescence staining using antibodies directed against ECP or MBP allows 
a more sensitive detection of eosinophils and extracellular granular protein deposits 
than just H&E staining. In BP, extracellular granular proteins have been detected 
either as separate deposits, as a thin coating on collagen bundles, so called flame 
figures, or associated with EETs (37-40).  
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That the presence of eosinophils is useful to distinguish BP from other 
blistering dermatoses such as dermatitis herpetiformis has long been recognized 
(41, 42). In skin lesions, mainly hypodense eosinophils were observed suggesting an 
activated state (43). Such activated eosinophils were located in the basement 
membrane zone and showed degranulation on keratinocytes (44). Recently, the 
expression of CD69, reflecting an activation of eosinophils, has been observed in BP 
(45). Eosinophil degranulation was most prominent in early erythematous and pre-
bullous (urticarial) lesions and thus seemed to precede blister formation (34). The 
accumulation of eosinophils in the skin correlated with the serum levels of BP 
autoantibodies of the IgE type in the subgroup of patients with IgE to BP230 (45). 
 
A Th2 milieu, and together with it, cytokines and chemokines affecting 
eosinophil recruitment, activation, and survival, have been found in lesional skin, 
blister fluids and peripheral blood of patients with BP. In the skin of BP and 
pemphigoid gestationis patients, a predominance of Th2 cytokines such as IL-4, IL-5 
and IL-13 has been observed (46, 47), even though elevated levels of both Th1 and 
Th2 chemokines were also found in the blood (48, 49). The serum levels of 
chemokines such as interferon-gamma induced protein (IP)-10, monokine induced 
by gamma-interferon (MIG), monocyte chemoattractant protein (MCP)-1 and eotaxin 
significantly correlated with the severity and activity of BP (50). Activated eosinophils 
were shown to preferentially attach to BP-skin in the presence of IL-5 (46, 47). 
Moreover, eotaxins, in particular CC chemokine ligands (CCL)11 and CCL26, and 
CCL17 (TARC) as well as their receptors CCR3 and CCR4, respectively, have been 
demonstrated in BP lesions (50-52). In addition to epithelial cells, eosinophils 
themselves expressed Th2 chemokines such as eotaxin and MCP-4, in particular 
upon stimulation with IL-5 (53).   
 
Blister fluids of BP have been reported to contain eosinophil chemotactic 
factors (54) and may stimulate eosinophil colony formation and activation (55). 
Eotaxin that was strongly expressed by the keratinocytes around blisters, was 
detected at high levels in blister fluids correlating with the number of tissue 
eosinophils (56). Moreover, blister fluids contain high amounts of Th2 cytokines 
including IL-5 (57) (Figure 1). 
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Peripheral blood eosinophilia is a common finding in BP and may range from 
5 to 43% (58). In BP patients, the levels of ECP and MPO were increased compared 
to controls and decreased upon immunosuppressive therapy (59). Elevated levels of 
IL-5 in serum and blister fluid correlated with ECP levels and disease severity (60, 
61). Anti-inflammatory therapies such as interferon-gamma or prednisolone plus 
intravenous immunoglobulins for patients with severe BP resulted in a decrease of 
IL-5 levels and blood eosinophil numbers in parallel with the clinical improvement 
(62, 63). Serum EDN levels strongly correlated with NC16A-specific IgG (64). It has 
been suggested that by releasing tissue factor (TF), eosinophils might activate the 
coagulation cascade in BP, subsequently resulting in inflammation, tissue damage, 
blister formation and possibly thrombotic risk (65). 
 
Eosinophils and tissue damage in BP 
Granule proteins have been observed in intact eosinophils as well as in extracellular 
granule deposits in the tissue of herpes gestationis (66). In addition to granule 
deposits in the tissue and flame figures, EETs have been detected in BP lesions 
(40). Interestingly, some of the EETs formed by eosinophils lining the dermal-
epidermal junction were directed toward the basement membrane zone (40) (Figure 
1).  
 
The 92 kD-gelatinase (MMP-9) was found to be actively expressed by 
eosinophils in BP lesions and to be present in blister fluids (67) (Figure 1). In vitro 
experiments showed that 92-kD gelatinase is able to cleave the extracellular, 
collagenous domain of recombinant 180-kD BP antigen (67). In addition to 
eosinophils, MMP-9, MMP-2 and MMP-13 were expressed by T cells (68). 
Gelatinase-deficient mice were resistant to the blistering effect of passively 
transfected anti-mBP180 antibodies (69). In an ex vivo BP model, the inhibition of 
leukocyte elastase and MMP-9 resulted in a suppression of blistering (70). 
 
Eosinophils and experimental BP models 
Upon injection of blister fluid of BP patients in the skin of a guinea pig, a mixed 
dermal infiltration containing mainly neutrophils, but also eosinophils, has been 
reported (71).  In SCID mice with engrafted human skin, the subcutaneous injection 
of an anti-basement membrane zone antibody led to an infiltration of eosinophils and 
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histologically evident subepidermal blister formation (72). Similarly, a mixed skin 
infiltrate composed of eosinophils, neutrophils and mast cells was observed in 
human skin grafted to nu/nu mice upon receiving IgE antibodies isolated from BP 
sera (73). The importance of neutrophils and neutrophil elastase in inducing 
subepithelial blister formation has been shown in various models of BP (74-76). The 
recruitment of neutrophils to the tissue depended on mast cell activation and 
degranulation following stimulation by macrophages (77-79). The function of anti-
mBP180 IgG was mediated by its Fc domain, whereas the F(ab')2 of IgG had no 
substantial pathogenic activity (79, 80). Fc gamma receptors II, III and IV have been 
reported to be involved in BP (81, 82).  Complement has been demonstrated to be 
necessary for blister formation in a mouse model, but was not essential in an ex vivo 
cryosection model of BP (79, 83). As shown for neutrophils, the generation of 
reactive oxygen species was a prerequisite for subepithelial blistering (76). 
 
The controversy about eosinophils and IgE in BP 
In a subgroup of BP patients, both tissue bound and circulating IgE autoantibodies 
directed to BP antigens can be detected and their presence correlated with disease 
severity (84-86). As mentioned above, when an IgE hybridoma to LABD97, a 
component of the shed ectodomain of bullous pemphigoid antigen 2, or IgE from BP 
patients were injected in animal BP models, erythema and intense scratching as well 
as eosinophil infiltration and degranulation of mast cells were observed in histology 
(72, 73). In humans, IgE anti-BP230 autoantibody levels showed a strong 
association with local eosinophil accumulation (45). However, it seems unlikely that 
eosinophils directly interact with IgE, since they lack functionally active high-affinity 
IgE receptors (FcεRI) (87, 88). In fact, BP antigen-specific degranulation of basophils 
and/or mast cells rather than eosinophils has been suggested as a mechanism by 
which IgE may contribute to lesion development (89). Recently, minimal expression 
of the FcεRI alpha-chain on eosinophils of BP patients has been shown, however, a 
functionality of the receptor has not been demonstrated (90). Moreover, the same 
authors reported that IgE to BP antigens did not mediate either eosinophil 
degranulation or eosinophil localization to the dermal-epidermal junction (65). 
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Eosinophil-induced DES in a cryosection model 
Eosinophilic cells derived from a human myeloid leukemia cell line were shown to 
localize at the dermal-epidermal junction in the presence of BP serum, but not upon 
incubation with control serum (64). The attachment to the DEJ was mediated by IgG 
and complement, whereas IgE had no effect (64). However, under these conditions, 
a subepithelial blistering could not be observed, presumably owing to a lack of 
eosinophil degranulation (64). In agreement with these findings, we have recently 
found that purified human eosinophils added to ex vivo skin sections in the presence 
of BP sera did not induce any DES while extensive DES was observed when the 
whole leukocyte fraction or purified neutrophils were used (90). However, eosinophils 
stimulated with IL-5 caused diffuse tissue damage including focal separation at the 
DEJ (91). Moreover, in the presence of BP sera, IL-5 activated eosinophils lined up 
at the DEJ and induced DES of approximately 20% of the DEJ (91). Under these 
conditions, eosinophil-induced DES depended on adhesion and FcγR binding, 
suggesting that BP autoantibodies directly activate eosinophils and/or attract them to 
the DEJ (91). Next, de Graauw et al. investigated molecular mechanisms involved in 
DES induced by IL-5 activated eosinophils in the presence of BP sera. Upon 
incubation with diphenyleneiodonium (DPI), a NADPH inhibitor, DES was decreased 
in a concentration-dependent manner (91). The observation that blocking of 
degranulation significantly reduced eosinophil-induced DES implied that toxic 
granule proteins directly contribute to blistering.  Moreover, a role for EETs was 
assumed since adding DNase to eosinophils which had been activated by IL-5 and 
BP sera significantly decreased DES in the cryosection model (91) (Figure 1).  
 
Therapeutic implications 
Recognizing eosinophils as major players in the pathogenesis of BP would open new 
perspectives for a targeted therapy. So far, topical and systemic steroids have been 
recommended as first line therapy of both localized and generalized BP (3). If 
steroids are not sufficient, immunosuppressives such as azathioprine, methotrexate, 
mycofenolate or chlorambucil might be added (3). Recently, rituximab and 
omalizumab, monoclonal antibodies targeting B cells (CD20) and IgE, respectively, 
have been shown to be effective in BP (92, 93). The mortality of patients with BP, in 
particular when treated with systemic steroids and immunosuppressive drugs, is 
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significantly increased as compared to the general population (94, 95). Thus, there is 
an urgent need for effective, well-tolerated and safe therapeutic tools for BP patients.  
The anti-IL-5 antibodies mepolizumab and reslizumab have demonstrated 
efficacy and safety in patients with allergic diseases and extrinsic hypereosinophilic 
syndromes (96). Moreover, blocking the IL-5 receptor led to a reduction of blood, 
bone marrow, and tissue eosinophilia in asthma patients (9). Based on the 
knowledge that IL-5 specifically regulates eosinophil production, activation and 
survival and on the observations that IL-5 is increased in the skin, blister fluids and 
peripheral blood in BP patients, there is a rationale for investigating the clinical 
effects of inhibiting IL-5 or its receptor in BP. A clinical trial studying the effect of 
mepolizumab on BP has been initiated (www.clinicaltrials.gov; NCT01705795). 
 
Since considerable amounts of eotaxins and their receptor CCR3 have been 
found in lesional BP, the inhibition of eosinophil recruitment by blocking eotaxins or 
CCR3 would be a further approach to treating BP. A clinical trial with bertilimumab, 
an anti-eotaxin-1 antibody, in BP is ongoing (www.clinicaltrials.gov; NCT02226146). 
 
Instead of inhibiting cytokines and chemokines regulating eosinophil function, 
T cells as their main source could be targeted. Current therapies directly (e.g. 
steroids, immunosuppressives) or indirectly (e.g. rituximab) suppress T cell function. 
A novel approach to inhibit Th2 cell activation is the application of a GATA-3 specific 
DNAzyme (98). Prostaglandin D2 (PGD2) has been reported to mediate activation 
and recruitment of eosinophils, basophils, and Th2 cells, as well as to promote an 
enhanced Th2 cytokine production through its receptor chemoattractant receptor-
homologous molecule on Th2 cells (CRTH2). Blocking CRTH2 has been shown to 
be effective in eosinophilic diseases such as asthma and eosinophilic esophagitis 
(99, 100). So far, studies with CRTH2 inhibitors in BP are lacking. In addition to 
inflammatory cells, epithelial cells may produce cytokines promoting Th2 reactions 
including eosinophil activation. In BP, keratinocytes were shown to express TSLP 
and eotaxin (6, 56). Thus, in addition to inhibiting eotaxin, suppressing TSLP would 
be worthwhile to study in BP.  
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Perspective 
Over the last decades, increasing evidence for a pathogenic role of eosinophils in BP 
in mediating tissue damage has been presented. The proof of an active contribution 
by eosinophils to subepithelial blister formation in BP patients, however, can only be 
indirectly adduced. Recently, eosinophils have been reported to be able to induce 
DES in a cryosection model of BP. So far, no animal model for BP showing that 
eosinophils contribute to blistering has yet been reported, but further evidence for the 
role of eosinophils in BP can be anticipated from clinical trials investigating targeted 
anti-eosinophil therapies in humans.  
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Figure legend 
Figure 1  A proposal for the role of eosinophils in the pathogenesis of bullous 
pemphigoid (BP). Eosinophils are produced, recruited and activated by cytokines 
released by keratinocytes (TSLP, eotaxin) and inflammatory cells, e.g. T cells (IL-5). 
Via their Fcγ receptor (FcγR), eosinophils attach to the hemidesmosomes at the 
dermal-epidermal junction. Upon activation, eosinophils produce reactive oxygen 
species (ROS), form eosinophil extracellular traps (EETs) and degranulate, releasing 
toxic granule proteins (ECP, MBP), metalloproteinase (MMP)-9 and IL-31 and, in this 
way, cause blister formation and itching. 
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